Products Palivizumab is commercially available as an injectable (Synagis). It has been approved in many countries since 1999. Structure and properties Palivizumab is a humanized IgG1k monoclonal antibody with a molecular mass of 148 kDa that binds to respiratory syncytial virus (RSV). The drug target is A-epitope of the fusion protein (F-protein) on the surface … Palivizumab
Products Panitumumab is commercially available as an infusion solution (Vectibix). It has been approved in many countries since 2008. Structure and properties Panitumumab is a recombinant, fully human IgG2 monoclonal antibody against EGFR. Effects Panitumumab (ATC L01XC08) has antitumor and antiangiogenic properties. The effects are due to binding to the epidermal growth factor receptor (EGFR). … Panitumumab
Products Ipilimumab is commercially available as a concentrate for the preparation of an infusion solution (Yervoy). It has been approved in many countries since 2011. Structure and properties Ipilimumab is a recombinant, humanized monoclonal antibody with an approximate molecular weight of 148 kDa. It is an IgG1-kappa immunoglobulin (IgG1κ). Effects Ipilimumab (ATC L01XC11) has indirect … Ipilimumab
Products Romosozumab was approved for injection in the United States and EU in 2019 and in many countries in 2020 (Evenity). Structure and properties Romosozumab is a humanized Ig2 monoclonal antibody with a molecular mass of 149 kDa produced by biotechnological methods. Effects Romosozumab (ATC M05BX06) promotes bone formation and, to a lesser extent, additionally … Romosozumab
Products Daclizumab was approved in the United States and EU in 2016 and in many countries in 2017 as a solution for injection for MS treatment (Zinbryta). In 2018, the drug was withdrawn from the market due to serious adverse effects. These adverse effects included liver damage and reports of encephalopathies (encephalitis, meningoencephalitis). Daclizumab had … Daclizumab
Products Nivolumab was approved in the United States in 2014 and in the in many countries and the EU in 2015 as a concentrate for the preparation of an infusion solution (Opdivo). Structure and properties Nivolumab is a human monoclonal antibody. It is an IgG4κ-immunoglobulin with a molecular mass of 146 kDa. Nivolumab is produced … Nivolumab
Products Tildrakizumab was approved as an injectable in the United States and EU in 2018 and in many countries in 2019 (ilumetri). Structure and properties Tildrakizumab is a humanized IgG1/k monoclonal antibody with an approximate molecular mass of 147 kDa. It is produced by biotechnological methods. Effects Tildrakizumab (ATC L04AC17) has immunosuppressive and anti-inflammatory properties. … Tildrakizumab
Products Belimumab is commercially available as a powder for the preparation of an infusion solution concentrate. It was approved in the EU in 2011 and in many countries in 2012 (Benlysta). In 2018, a solution for subcutaneous injection was registered (autoinjector and prefilled syringe). Structure and properties Belimumab is a human IgG1λ monoclonal antibody with … Belimumab
Products Alirocumab was approved in the United States and EU in 2015 and in many countries in 2016 as the first agent in the group of PCSK9 inhibitors in the form of a solution for injection (Praluent). Structure and properties Alirocumab is an IgG1 monoclonal antibody with a molecular mass of 146 kDa. Effects Alirocumab … Alirocumab
Products Cemiplimab was approved in the United States in 2018, in the EU in 2019, and in many countries in 2020 as a concentrate for the preparation of an infusion solution (Libtayo). Structure and properties Cemiplimab is a human IgG4 monoclonal antibody with a molecular mass of 146 kDa produced by biotechnological methods. Effects Cemiplimab … Cemiplimab
Products Dupilumab was approved as a solution for injection in the United States and EU in 2017 and in many countries in 2019 (Dupixent). Structure and properties Dupilumab is a human recombinant IgG4 monoclonal antibody with a molecular mass of 147 kDa. It is produced by biotechnological methods. Effects Dupilumab (ATC D11AH05) has anti-inflammatory and … Dupilumab
Products Durvalumab was approved as an infusion product in the United States in 2017 and in many countries and the EU in 2018 (Imfinzi). Structure and properties Durvalumab is a human IgG1κ monoclonal antibody. It is produced by biotechnological methods. Effects Durvalumab (ATC L01XC28) has selective immunostimulatory and antitumor properties. The effects are due to … Durvalumab